June 1, 2020 - The court denied the defendants' motion to dismiss.

July 2, 2019 - A motion to dismiss the corrected second amended complaint was filed.

June 3, 2019 - A correction to the second amended complaint was filed.

May 30, 2019 - A second amended complaint was filed.

March 31, 2019 - The court granted the defendants' motion to dismiss. The plaintiffs were given leave to amend the complaint.

January 26, 2018 - A motion to dismiss the amended consolidated complaint was filed.

October 4, 2017 - An amended consolidated complaint was filed.

June 9, 2016 - An investor in shares of Immunomedics Inc (NASDAQ: IMMU) filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Immunomedics Inc in connection with certain allegedly false and misleading statements made between April 20, 2016 and June 2, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of Immunomedics Inc (NASDAQ: IMMU) common shares between April 20, 2016 and June 2, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between April 20, 2016 and June 2, 2016 the defendants made false and/or misleading statements and/or failed to disclose that the abstract for IMMU-132 that Immunomedics Inc submitted to the American Society of Clinical Oncology (“ASCO”) for presentation at the 2016 ASCO Annual Meeting contained previously disclosed results from a mid-stage study, that Immunomedics Inc had misrepresented to ASCO that its abstract for IMMU-132 contained only updated and previously undisclosed data, that the foregoing misrepresentation was a violation of ASCO policy and made Immunomedics Inc’s IMMU-132 presentation subject to removal from the 2016 ASCO Annual Meeting schedule, and that as a result of the foregoing, Immunomedics Inc’s public statements were materially false and misleading at all relevant times.

On June 2, 2016, after the market closed, media outlets reported that the American Society of Clinical Oncology ( ASCO ) had removed a scheduled presentation by Immunomedics Inc regarding the Company's IMMU-132 breast cancer drug from the American Society of Clinical Oncology's annual meeting. The American Society of Clinical Oncology stated that Immunomedics Inc had misrepresented that the Company's abstract for IMMU-132 contained updated and previously undisclosed results from a mid-stage study, when in fact the IMMU-132 data that Immunomedics Inc submitted were old and previously seen.

Shares of Immunomedics Inc (NASDAQ: IMMU) declined to as low as $3.83 per share on June 6, 2016.